Matinas Biopharma Holdings Inc (MTNB)
$0.62
Performance
- $0.59$0.63$0.62
4.47%
Downside
Day's Volatility :5.98%
Upside
1.59%
- $0.50$21.50$0.62
19.35%
Downside
52 Weeks Volatility :97.67%
Upside
97.12%
Returns
| Period | Matinas Biopharma Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -91.14% | 0.0% |
6 Months | -92.67% | 0.0% |
1 Year | -94.63% | 0.0% |
3 Years | -98.86% | -26.4% |
Highlights
Market Capitalization | 3.7M |
Book Value | $3.81 |
Earnings Per Share (EPS) | -5.5 |
PEG Ratio | 0.0 |
Wall Street Target Price | 30.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -50.87% |
Return On Equity TTM | -97.59% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -13.5M |
EBITDA | -23.4M |
Diluted Eps TTM | -5.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.35 |
EPS Estimate Next Year | -3.0 |
EPS Estimate Current Quarter | -0.02 |
EPS Estimate Next Quarter | -0.02 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 4738.71%
Technicals Summary
Sell
Neutral
Buy
Matinas Biopharma Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Matinas Biopharma Holdings Inc | -84.06% | -92.67% | -94.63% | -98.86% | -99.0% |
 Regeneron Pharmaceuticals, Inc. | -23.02% | -19.16% | -1.76% | 21.74% | 130.02% |
 Biontech Se | -11.89% | 11.38% | 3.87% | -59.87% | 425.69% |
 Alnylam Pharmaceuticals, Inc. | -10.25% | 70.55% | 52.64% | 49.13% | 178.13% |
 Vertex Pharmaceuticals Incorporated | -0.07% | 9.83% | 41.1% | 156.97% | 130.46% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Matinas Biopharma Holdings Inc | NA | NA | 0.0 | -4.35 | -0.98 | -0.51 | NA | 3.81 |
Regeneron Pharmaceuticals, Inc. | 20.33 | 20.33 | 1.23 | 44.95 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.02 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.04 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.3 | 0.52 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Matinas Biopharma Holdings Inc | Buy | $3.7M | -99.0% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.2B | 130.02% | 20.33 | 33.61% |
Biontech Se | Buy | $26.7B | 425.69% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.7B | 178.13% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $127.4B | 130.46% | 32.84 | -4.51% |
Insights on Matinas Biopharma Holdings Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.09M → -1.09M (in $), with an average decrease of 200.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -5.82M → -4.27M (in $), with an average increase of 17.8% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.6% return, outperforming this stock by 147.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 49.1% return, outperforming this stock by 148.0%
Company Information
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
Organization | Matinas Biopharma Holdings Inc |
Employees | 32 |
CEO | Mr. Jerome D. Jabbour J.D. |
Industry | Health Technology |
Discover More
Cactus Acquisition Corp 1 Ltd
$0.62
-2.27%
Rigel Resource Acquisition Corp
$0.62
-2.27%
Fortune Rise Acquisition Corp
$0.62
-2.27%
P.a.m. Transportation Svcs
$0.62
-2.27%
Onyx Acquisition Co. I
$0.62
-2.27%
Blockchain Coinvestors Acquisition Corp.
$0.62
-2.27%
Apollomics Inc
$0.62
-2.27%
Castor Maritime Inc
$0.62
-2.27%
Aam Brentview Dividend Growth Etf
$0.62
-2.27%